Background: A delicate balance between positive and negative regulatory mechanisms during T-cell activation determines the specificity and magnitude of an immune response. Phosphoinositide 3-kinase (PI 3-kinase) is activated by a diverse set of receptors that determine T-cell function, including the T-cell antigen receptor (TCR), the costimulatory receptor CD28, and negative regulators of T-cell activation such as CTLA-4. PI 3-kinase is also regulated by the haematopoietic cytokines that determine T-cell differentiation and lymphocyte proliferation. PI 3-kinase can thus dynamically influence the outcome of the immune reactions at various stages. In this study, we investigated the importance of PI 3-kinase in TCR-directed T-cell activation using activated or inhibitory versions of PI 3-kinase.
Background
During T-cell activation, both positive and negative regulatory signalling cascades are vital for a balanced immune response and immune homeostasis. T-cell activation is orchestrated by the T-cell antigen receptor (TCR) and a plethora of accessory molecules such as integrins, the tyrosine phosphatase CD45, the coreceptors CD4 and CD8, and the costimulatory receptor CD28 [1] [2] [3] [4] [5] [6] . These regulatory receptors thus determine the outcome of TCR engagement by modulating TCR function and influencing the thresholds of TCR occupancy required to initiate a T-cell immune reaction.
Phosphoinositide 3-kinase (PI 3-kinase) is activated during T-cell activation but its function in T cells is as yet poorly understood [7, 8] . PI 3-kinase comprises a regulatory p85 subunit and a catalytic p110 subunit which phosphorylates phosphatidylinositol 4,5-bisphosphate generating phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P 3 ) [9, 10] . Elevation of cellular levels of PI(3,4,5)P 3 correlates with PI 3-kinase action. Studies of PI 3-kinase activation in T cells established that the TCR and CD28 can act in concert to give a substantial rise in PI(3,4,5)P 3 levels [11] . Intriguingly, PI 3-kinase is also associated with inhibitory receptors such as CTLA-4 [12, 13] or CD5 [14, 15] . Moreover, PI 3-kinase activity is regulated by cytokines such as IL-2/IL-4 which have a critical role in downregulating immune hyperactivity [16] . It is thus clear that receptors that activate PI 3-kinase can have major functions as negative regulators of the immune system. Signal transduction events from the TCR are subject to important autoregulatory and pararegulatory negativefeedback control mechanisms: it is increasingly recognized that receptors on T cells such as CTLA-4, inhibitory MHC class I molecules and cytokine receptors can generate terminating signals, which are extremely important in immune homeostasis [16] [17] [18] [19] [20] . There is only a primitive understanding of the effector molecules that downmodulate TCR signal transduction, particularly in the context of negative-feedback mechanisms generated by the TCR itself. As PI 3-kinase can cause pleiotropic function, it could be critical for defining and revising the biological responses from the TCR by eliciting negative signals.
We have employed genetic approaches using activated or inhibitory mutants of PI 3-kinase to analyze the normal cellular functions of the enzyme in T-cell activation governed by the TCR. We examined the importance of PI 3-kinase in TCR-induced transcription factor responses because transcription factors coordinate and implement various activating or inhibitory input messages and are ultimately responsible for fine-tuning the genetic program. Here, we report that signals downstream from PI 3-kinase impair TCR-controlled transcription from the NF-AT ('nuclear factor of activated T cells') response element, whereas these signals do not interfere with the signalling pathways that lead to gene transcription mediated by AP1 or serum response factor (SRF). We show that the serine/threonine protein kinase B (PKB; also termed c-Akt) is activated by PI 3-kinase, but that active PKB cannot substitute for active PI 3-kinase in the abolition of TCR-triggered transactivation by NF-AT. Moreover, a putative effector of PI 3-kinase action, the GTPase Rac, does not appear to mediate the negative regulatory effect of PI 3-kinase on NF-AT response elements. It is therefore likely that an as yet unknown effector protein controls the inhibitory action of PI 3-kinase on regulation by NF-AT. Finally, we demonstrate that abrogation of endogenous PI 3-kinase activity by expression of inhibitory mutants of PI 3-kinase enhances TCR-induced NF-AT transactivational activity. These results reveal that PI 3-kinase can induce negative regulatory signals in T cells and thus implicate PI 3-kinase as a selective modulator of the genetic program initiated by TCR engagement.
Results

PI 3-kinase signals block TCR-induced transcription from NF-AT response elements
Immediate responses to TCR triggering include the activation of transcription factors such as AP1, SRF and NF-AT [21] which are ultimately important for cytokine gene expression. Here, we have analyzed the consequences of PI 3-kinase activation on transcription-factor regulation by the TCR. The Jurkat T-cell line was transfected with reporter genes responsive to different transcription factors together with a constitutively active form of PI 3-kinase, rCD2p110, comprising the extracellular and transmembrane domains of the rat CD2 (rCD2) cell surface antigen fused to the amino-terminal domain of the p110␣ catalytic subunit of PI 3-kinase [22] . As controls, cells were similarly transfected with rCD2p110-R/P, a chimera mutated at position 1130 thus catalytically inactivating the kinase activity of the fusion protein [22] ; rCD2p85, a chimera comprising the rCD2 extracellular and transmembrane domains linked to the amino terminus of the p85␣ regulatory subunit of PI 3-kinase [22] ; and wildtype rCD2. Expression of the rCD2-PI 3-kinase chimeras was confirmed by flow cytometry (Fig. 1a) .
The induction of the transcription factor NF-AT by triggering of the TCR or by the combined action of calcium ionophore and phorbol ester (phorbol 12,13-dibutyrate; PdBu) was studied. TCR induction of NF-AT was completely abrogated by expression of the activated PI 3-kinase chimera, rCD2p110 (Fig. 1b) . The repressive effect of the active PI 3-kinase on NF-AT induction was selective because only TCR responses were prevented and those of calcium ionophore and phorbol ester were unaffected (Fig. 1c) . TCR induction of NF-AT still occurred in the presence of wild-type rCD2, 'kinase-dead' rCD2p110-R/P or rCD2p85 (Fig. 1b,c) , showing that the inhibitory effect of rCD2p110 on TCR/NF-AT responses requires the lipid kinase activity of PI 3-kinase [22] .
It was noted that expression of rCD2p85 could induce a low level of NF-AT activity in the absence of stimulation. We have observed previously that rCD2p85 acts as a moderate inhibitory mutant of PI 3-kinase signalling pathways, and this could explain the potentiating effect of rCD2p85 on NF-AT transcriptional activity (see Fig. 5 ). Signalling pathways are initiated and modulated differentially in divergent cell types, therefore the magnitude or quality of a response is dependent upon cell context. We examined the effects of the constitutively active PI 3-kinase on TCR/NF-AT responses in the murine T-cell line EL4. The data in Figure 1d show that TCR-mediated induction of NF-AT was also suppressed in EL4 cells expressing the activated rCD2p110 chimera; however, suppression was not as complete as in Jurkat cells. This incomplete inhibition might occur because EL4 cells exhibit partial constitutive activation of calcium/calcineurin signalling pathways [23] , which is one of the crucial signals required for NF-AT regulation [24] .
PI 3-kinase signals do not impair TCR-mediated induction of AP1-or SRF-activated gene transcription
We next explored the role of PI 3-kinase signals on TCRmediated induction of the transcriptional activity of the c-fos serum response element (SRE) or AP1-driven enhancer elements which are both central to the regulation of immediate early genes. Activation at the SRE is mediated by p21Ras/Raf/Erk (MAP kinase) pathways that can be initiated in T cells by triggering of the TCR or by phorbol ester (Fig. 2a) . Expression of rCD2p110 had no stimulatory effect on SRE activity but more importantly, it did not compromise induction of SRE activity by TCR cross-linking or treatment with phorbol ester. The transcriptional activity of AP1 complexes induced by triggering of the TCR or treatment with phorbol ester plus ionomycin was also unaffected by coexpression of rCD2p110 (Fig. 2b) . Expression of a constitutively active PI 3-kinase therefore has a selective modulatory effect on the repertoire of transcription factor pathways activated by the TCR: signals downstream of PI 3-kinase negatively regulate the TCR signalling pathways that lead to NF-AT-mediated transactivation but do not affect the TCRmediated induction of SRE and AP1-responsive elements.
PKB is stimulated by PI 3-kinase but does not inhibit transactivation by NF-AT
PI 3-kinase signals are able to activate the serine/threonine kinase PKB in fibroblasts [25, 26] . This PI 3-kinase pathway is important in regulating cell-survival responses in fibroblasts and neuronal cells [27, 28] . The negative effects of active PI 3-kinase on TCR-mediated NF-AT responses and its lack of effect on TCR-induced SRE and AP1 activation prompted us to examine the effects of rCD2p110 on PKB activity in Jurkat cells. TCR triggering led to an increase in PKB activity (Fig. 3a) . Moreover, expression of the membrane-localized PI 3-kinase, rCD2p110, was sufficient to stimulate PKB activity to a level comparable to that initiated by triggering of the TCR/CD3 complex (Fig. 3a) . PI 3-kinase action thus does not completely antagonize signalling from the TCR but can also positively regulate proximal TCR signal transduction events. We next investigated whether PKB was involved in transmitting the inhibitory effects of PI 3-kinase on TCR signalling. Expression of a constitutively active PKB, gagPKB, did not mimic the effect of active PI 3-kinase in the abrogation of TCR-mediated NF-AT induction (Fig. 3b) . PKB is thus not a candidate for mediating the inhibitory effect of PI 3-kinase on TCR signalling.
Expression of V12Rac does not abrogate transactivation by NF-AT but does induce SRF and AP-1 activity
We have shown recently that the active PI 3-kinase, rCD2p110, can initiate signalling pathways mediated by the GTPase Rac that lead to actin cytoskeleton rearrangements in fibroblasts [22] . Rac can deliver signals for transcriptional activation including stimulation of stress-activated protein kinases [29] [30] [31] . We tested the possibility that Rac might mediate the effects of PI 3-kinase on NF-AT activity. Expression of constitutively active Rac, V12Rac, did not substitute for PI 3-kinase in the inhibition of TCR-mediated NF-AT responses (Fig. 4a) . Moreover, V12Rac expression stimulated transcription regulated by SRF (Fig. 4b) and AP1 (Fig. 4c) , as did expression of Dbl (Fig. 4b,c) , a guanine nucleotide exchange factor for Rho family GTPases that activates endogenous Rac and Rho [32] . Expression of rCD2p110 failed to elicit transcriptional activity from the SRE or from AP1 elements indicating that signals from PI 3-kinase do not apparently initiate Racmediated transcription-factor pathways in T cells. In addition, previous studies have shown that expression of an inhibitory Rac mutant, N17Rac, suppresses rather than potentiates TCR-induced NF-AT signal transduction cascades [33] . These data demonstrate that effector pathways distinct from PKB-or Rac-governed signalling cascades must mediate the effects of PI 3-kinase on TCR function.
Expression of inhibitory mutants of PI 3-kinase enhances TCR-induced NF-AT responses
It has been known for some time that TCR activation of NF-AT is transient and subject to as yet uncharacterized negative-feedback regulation [34] [35] [36] . The inhibitory effects of active PI 3-kinase on TCR-mediated transactivation by NF-AT coupled with the fact that the TCR rCD2p110-R/P rCD2p110 Empty rCD2p110-R/P rCD2p110 Empty activates PI 3-kinase raise the possibility that PI 3-kinase may elicit deactivation of TCR-provoked NF-AT responses. To test this hypothesis, we examined the effect of p85⌬, an inhibitory mutant of PI 3-kinase, on TCRmediated induction of NF-AT. The p85⌬ mutant corresponds to a p85 regulatory subunit lacking the binding site for the p110 catalytic subunit and therefore prevents regulation and recruitment of the active enzyme complex to the plasma membrane [37] . Expression of p85⌬ led to a small but reproducible basal induction of NF-AT activity, and strikingly synergized with TCR stimulation to induce NF-AT transcriptional activity (Fig. 5a,b) . In contrast, p85⌬ had no effect on TCR-mediated induction at the SRE in parallel experiments (Fig. 5c) . The potentiating effect of p85⌬ is consistent with the notion that PI 3-kinase signals antagonize the TCR signals that initiate NF-AT transcriptional activity.
Discussion
As a delicate balance between positive and negative signals is obligatory for an immune response, it is important to characterize the full spectrum of intracellular molecules that integrate these input signals. Although substantial progress has been made to delineate positive events, much less is known about effectors that negatively modulate or terminate T-cell activation. The data presented here reveal a previously unrecognized function for PI 3-kinase as a selective negative regulator of TCR responses. The importance of this negative signalling role for PI 3-kinase is underscored by its selective mode of action: PI 3-kinase signals are sufficient to stimulate PKB, a serine/threonine kinase involved in the regulation of survival responses in several cell systems; in contrast, PI 3-kinase signals abolish TCR-controlled NF-AT transactivation but allow TCR-mediated induction of AP1 or SRE. Interestingly, an active allele of PKB did not abrogate NF-AT activity triggered by the TCR, nor did expression of an activated form of the GTPase Rac, a second well characterized effector of PI 3-kinase, abolish NF-AT activity. This finding implicates an as yet uncharacterized effector pathway as the mediator of PI 3-kinase regulation of the TCR-induced NF-AT response (Fig. 6 ).
The transcriptional activation of NF-AT is complex process that involves translocation of the cytosolic NF-AT component from the cytoplasm to the nucleus, where it associates with its nuclear component, which contains Fos/Jun (AP-1) family members that facilitate the DNAbinding ability and transcriptional activity of NF-AT [38] . The precise mechanism for NF-AT inhibition by PI 3-kinase awaits analysis. However, NF-AT induction by the TCR requires the coordinate action of signalling pathways mediated by the phosphatase calcineurin, the GTPase p21Ras, and may involve the adaptor protein SLP-76 and Vav [3, 4] . PI 3-kinase could thus exert its regulatory effects on NF-AT induction at multiple sites. Cytokine gene expression upon activation of T cells is a transient phenomenon subject to critical negative-feedback control. NF-AT family members govern the transcription of a number of genes including those for the cytokines IL-2, IL-3, and IL-4, and for CD40 ligand and Fas ligand [38, 39] . In this respect, it has been recognized for several years that there are negative-feedback signalling mechanisms for the TCR-mediated induction of NF-AT [34] [35] [36] . These downregulating mechanisms are likely to be responsible for the transience of cytokine gene expression during T-cell activation. The data presented in this paper, showing the reciprocal effects of activated and inhibitory mutants of PI 3-kinase on TCR-delivered NF-AT responses, are consistent with a model in which PI 3-kinase has a negative-feedback or modulatory role in the induction of NF-AT activity by the TCR (Fig. 6) . TCR triggering itself activates PI 3-kinase and the inhibitory PI 3-kinase signals described herein might act as a physiologically relevant homeostatic control mechanism in TCR function that temporally restricts cytokine production to a limited period of T-cell activation.
Moreover, TCR-induced cytokines, such as IL-2 and IL-4, act as growth factors in autocrine loops to drive T cells through the cell cycle [40, 41] . These growth factors are powerful activators of PI 3-kinase [42] [43] [44] and a PI 3-kinase-mediated NF-AT inhibitory pathway would ensure that cytokine production is restricted to cells that have not yet received a signal to proliferate. There is little reason for a cell that is committed to proliferate to continue to produce growth-regulatory cytokines (Fig. 6) . Intriguingly, it has been reported that NF-ATp/NF-AT1-deficient mice show enhanced immune responses [39, 45] , which suggests that NF-AT family proteins are involved in downregulating immune responses. PI 3-kinase downregulation of NF-AT function would thus not only terminate the positive growth regulatory signals generated by NF-AT, but would also modulate the negative feedback functions of NF-AT.
There could also be broader implications for the terminating effects of PI 3-kinase on TCR function described in this study: molecules such as CTLA-4 that negatively regulate T-cell activation [17] [18] [19] also associate with PI 3-kinase [12] . Previous studies have ascribed the negative effects of CTLA-4 signalling to the association of this receptor with the tyrosine phosphatase SHP-2 [46] . However, there is no direct evidence that SHP-2 acts to downregulate T-cell functions and it is noteworthy that the p85 subunit of PI 3-kinase and SHP-2 interact with the same phosphotyrosine motif, Tyr-Val-Lys-Met, in the cytoplasmic domain of CTLA-4 via their SH2 domains [12, 46] . PI 3-kinase could thus be a candidate for mediating the negative effects of CTLA-4 on T-cell action. In addition, PI 3-kinase could play a role in the negative signalling pathways initiated by cytokines such as IL-2 and IL-4. These issues are obviously complicated UCHT-1 (µg ml -1 ) p85∆
Empty by the fact that PI 3-kinase signals will undoubtedly be influenced by other signalling pathways that are concurrently active within a cell.
PI 3-kinase may thus have multiple roles and the precise outcome of PI 3-kinase activation may be determined by the number of different receptors that simultaneously engage PI 3-kinase (quantitative modulation) (Fig. 6 ) and/or the disparate effector pathways that are induced by different receptors and can 'cross-talk' to PI 3-kinase effector cascades (qualitative modulation). In this context, it has been well documented that different subpopulations of T cells can vary dramatically in their cellular responsiveness to signalling pathways. A clear example of this variability in the context of 'negative' signalling is the induction of apoptosis by the death-inducing receptor Fas: cells expressing Fas antigen can vary markedly in their susceptibility to Fas-mediated apoptosis. In future studies, it will be of interest to determine whether negative signals delivered by PI 3-kinase resulting in inhibition of TCR-controlled NF-AT induction, are ubiquitous with respect to function or whether they are selective for certain T-cell populations.
As shown in this paper, PI 3-kinase signals will modulate patterns of transcription factor activity and hence alter gene expression regulated by the TCR in a specific manner, rather than by generally disrupting TCR responses and operating as a simple 'off signal' for the TCR. Modulation of TCR function occurs at repeated points during T-cell development and activation, for example, during the processes of positive and negative selection in the thymus, and in T-cell activation compared with T-cell anergy. The data presented here identify PI 3-kinase as a determinant of TCR-signalling thresholds for activation.
Conclusions
During T-cell activation and proliferation, PI 3-kinase is activated by multiple receptors, such as the TCR, CD28, IL-2R, IL-4R or CTLA-4, that can positively or negatively regulate these processes. Hence, PI 3-kinase is likely to have pleiotropic functions. In these studies, we have defined one further function of PI 3-kinase in modulating TCR-controlled transcription factor responses, in that it selectively downregulates TCR-mediated induction of NF-AT transcriptional activity. This identifies PI 3-kinase as a determinant of negative signalling pathways in T-cell activation and lymphocyte homeostasis.
Materials and methods
Plasmids
The plasmids for the following DNA constructs have been described previously NF-AT.CAT (CAT, chloramphenicol acetyl transferase) and AP1.CAT [33] , SRE.CAT [47] , HA-PKB and gagPKB [48] , p85⌬ [37] , V12Rac and Dbl [22] . The rCD2p85, rCD2p110 and rCD2p110-R/P constructs, as well as the rCD2 cDNA have been described previously [22] and were subcloned into the pEF-BOS expression vector.
Cell culture and transient transfections
Jurkat T cells (JHM1 2.2) [49] were maintained in RPMI 1640 supplemented with 10% foetal calf serum, 2 mM L-glutamine, 100 g ml -1 Research Paper Negative role for PI 3-kinase in TCR events Reif et al. 291
Figure 6
Schematic representation of the selective negative role of PI streptomycin, and 100 units ml -1 penicillin; EL4 murine thymoma cells were also maintained in this medium but with the addition of 10 M ␤-mercaptoethanol [50] . Jurkat and EL4 T cells were transfected by electroporation with 20-40 g plasmid DNA. Amounts of plasmid DNA were kept constant per cuvette by adding vector plasmid. Jurkat cells (1.0-1.5 × 10 7 cells in 0.5 ml) were pulsed at 310 V and 960 F. EL4 cells (1.0-1.5 × 10 8 cells in 0.29 ml) were pulsed at 250 V and 960 F. The following amounts of plasmid were used unless indicated otherwise: 15 g of the following plasmids: pEF-empty, pEFrCD2p110, pEF-rCD2p110-R/P, pEF-rCD2p85, pEF-rCD2, or pSG5-gagPKB; 10 g of the following plasmids: pSG5-HA-PKB, pcDSRa-p85⌬, pEF-V12Rac, pCMV-Dbl; 15 g of NF-AT.CAT, 5 g of SRE.CAT and 2 g of AP1.CAT. For gene reporter assays, cells were stimulated 3 h to 6 h after transfection. Inductions were as follows, unless indicated otherwise: 50 ng ml -1 phorbol 12,13 dibutyrate (PdBu; Calbiochem), 500 ng ml -1 ionomycin (Ca 2+ salt; Calbiochem). TCR crosslinking was achieved by stimulating Jurkat cells with 5 g ml -1 of the human CD3 antibody UCHT1 or by stimulating EL4 cells with 10 g ml -1 plate-bound murine CD3 antibody 2C11.
Immunofluorescence staining and flow cytometry
Cells transfected with rCD2 chimeras were subjected to immunofluorescent staining and flow cytometry using 0.6 g ml -1 Ox34 monoclonal antibody, and for control staining mouse IgG (Sigma), followed by fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG (DAKO) using standard protocols.
Gene expression analysis
Cells were harvested and lysed in 200 l lysis buffer (0.65% NP40, 10 mM Tris pH 8, 1 mM EDTA, 150 mM NaCl) 14-16 h after inductions. Gene expression assays were carried out essentially as described [33] except that the following assay conditions were used: 180 mM Tris pH 8, 7.3 mM [ 14 C]acetyl coenzyme A (0.05 Ci), 0.174 mM acetyl coenzyme A, 1.74 mM chloramphenicol. The CAT activity is presented as percentage conversion.
PKB kinase assays
Jurkat cells were stimulated with 5 g ml -1 UCHT-1 monoclonal antibody and lysed (120 mM NaCl, 50 mM Hepes pH 7.4, 10 mM NaF, 1 mM EDTA, 40 mM ␤-glycerophosphate pH 7.5, 1% NP40, 0.1 mM PMSF, 0.1 mM Na 3 VO 4 ) 16 h after transfection. Postnuclear cell extracts corresponding to 1 × 10 6 live cell equivalents were incubated with 2 g 12CA5 anti-haemagglutinin (HA) monoclonal antibody (Boehringer Mannheim). Immune complexes were precipitated with protein G-Sepharose beads (Sigma). The immunoprecipitates were washed twice in lysis buffer, twice in high salt wash buffer (500 mM LiCl, 100 mM Tris pH 7.5, 1 mM EDTA pH 7.5) and once in PKB assay buffer (50 mM Tris pH 7.5, 10 mM MgCl 2 , 1 mM DTT). The reaction was initiated by the addition of 15 l PKB reaction buffer containing 3 mCi ␥-[ 32 P]ATP, 50 mM ATP, 7.3 mM MgCl 2 , 730 M DTT, 500 nM protein kinase inhibitor (Sigma), 40 mM Tris pH 7.5, and 2.5 g histone 2B (H2B) (Boehringer Mannheim). After 30 min at 25°C, the reaction was terminated by adding reducing SDS-PAGE sample buffer and boiling. Proteins were resolved by SDS-PAGE and 32 P-labelled H2B proteins were detected by autoradiography. The levels of HA-PKB protein in each immunoprecipitate were assessed by western blot analysis with a Rac-PK-CT antibody towards PKB (Upstate Biotechnology Incorporated), using the ECL detection system (Amersham).
